REGENXBIO (RGNX) Stock Forecast & Price Target

Regenxbio is well-positioned for success in the gene therapy industry thanks to its strong intellectual property, with patents extending into the 2030s. Although recent clinical hold decisions by the FDA may have caused some concern, there is no evidence of neoplasm in patients receiving similar treatments and no impact on other clinical studies. With a promising pipeline and a strong safety track record, Regenxbio presents a compelling opportunity for future growth and innovation.

Regenxbio is a biotech company focused on gene therapy treatments for rare diseases and retinal conditions, with a price target of $32 per share. However, the recent CRL from the FDA for their gene therapy for Mucopolysaccharidosis II raises concerns about potential delays in product development and commercialization. Additionally, competition in the gene therapy space and the potential need for additional capital may lead to share dilution and hinder the company's progress.